The 2-Minute Rule for nardeterol
The overall conclusions of those scientific studies are that ximelagatran is not inferior to plain therapy for the acute therapy of DVT which is outstanding to placebo for prolonged secondary prevention of recurrent DVT and/or PE.In 2006, its producer AstraZeneca declared that it would not make an effort to current market ximelagatran immediately a